Rolf Mahlberg

TL;DR: In this article, the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin, and doceteaxel) as a perioperative therapy for patients with locally advanced, resectable tumours was reported.

TL;DR: Almost half of patients with Ph+ ALL receiving imatinib for MRD positivity after SCT experience prolonged DFS, which can be anticipated by the rapid achievement of a molecular complete remission (CR).

TL;DR: The FLYER trial assessed whether four cycles of CHOP plus six applications of rituximab are non-inferior to six cycles of R-CHOP in a population of patients with B-cell non-Hodgkin lymphoma with favourable prognosis, demonstrating the non- inferiority of the four-cycles regimen.

TL;DR: The triple combination improved response rates and progression-free survival in the locally advanced subgroup and in the subgroup of patients aged between 65 and 70 years but not in the metastatic group or in patients aged 70 years and older.

TL;DR: This trial evaluates the addition of trastuzumab (tras) and pertuzumAB (per) to FLOT for resectable, esophagogastric adenocarcinoma (EGA).